Choose Your Language:
Posted by: The Sumaira Foundation in News & Announcements
In 2014, The Sumaira Foundation (TSF) launched to raise awareness of neuromyelitis optica spectrum disorder (NMOSD) and create a community of people brought together through shared experiences.
As our network of patients, caregivers and supporters grew, the science was evolving.
Researchers found patients who exhibited the same signs and symptoms as NMOSD, but the antibody and disease process differed. These patients’ immune systems create antibodies that attack the myelin oligodendrocyte glycoprotein (MOG) and damage the nerves.
Doctors have now acknowledged that myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD) is its own diagnosis. Many patients in our NMOSD community have been reevaluated and given the MOG-AD diagnosis. Due to its distinct pathophysiological features, MOG-AD is emerging as its own disease entity; the presence of autoantibodies against MOG distinguishes it from related neuroinflammatory and demyelinating disorders. MOG-AD is a rare neuroimmune condition that targets the MOG protein which is located on the surface of myelin sheaths in the central nervous system. Common symptoms include vision loss, color vision deficiency, paralysis, paraparesis, weakness, numbness, spasticity, vomiting, hiccups, seizures, and bladder/bowel dysfunction.
After all, family is family, and we are more powerful…together. As a community, the distinction between NMOSD and MOG-AD has always been negligible. The Foundation has actively supported MOG-AD patients by developing advocacy tools like the MOGmentum series and Voices of MOG stories.
As of March 2022, TSF has invested over $160,000 in MOG-AD-related research grants. We have produced 10 MOG-AD inclusive webinars and are increasing MOG-AD representation in our Demystifying NMO podcast with our partner, the Connor B Judge Foundation.
We hope you join us in raising awareness this April during the 1st MOG-AD Awareness Month.
Sponsored by UCB Pharma, this clinical trial marks the first-ever clinical trial specifically for adults living with MOG-AD. cosMOG is a Phase 3 (NCT05063162) study designed to assess the efficacy, safety, and tolerability of rozanolixizumab for treatment of adult participants with MOG-AD. To learn more, click the button below:
Graphics are available in English, Danish, Dutch, French, German, Italian, Portuguese, and Spanish. Right click on the image to save and share!
